CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 99 enrolled
Drug / intervention
Isavuconazoledrug
Likely dose
Isavuconazole 372 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03149055
NCT03149055Phase 2Completed
CompareCT.gov

A Single Center, Open-label Trial of Isavuconazole Prophylaxis Against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Memorial Sloan Kettering Cancer Center·interventional·Posted May 11, 2017·Updated May 16, 2025

In Brief

A Phase 2 clinical trial evaluating Isavuconazole for Hematologic Malignancy and Myeloproliferative Disorder. Completed, enrolled 99 participants across 1 site.

Detailed Summary

The purpose of this study is to study the effects of isavuconazole in preventing fungal infections in patients who have had a hematopoietic stem cell transplant (HCT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematologic Malignancy, Myeloproliferative Disorder
CountriesUnited States
CollaboratorsAstellas Pharma US, Inc.

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMay 11, 2017
Enrollment StartMay 4, 2017
Primary CompletionAug 20, 2019
Study CompletionNov 8, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.1 years ago

Interventions

Isavuconazoledrug

Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.